The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap. The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) patients.

Creative Ventures led the round with participation from IAG Capital Partners, C3 Ventures, Olima Ventures, Texas Halo Fund, Cowtown Angels, and SP Investment Fund, among other prominent investors, following their participation in Y Combinator's Summer 2020 Batch. The close brings the funding to date to more than $6 million. This includes prestigious non-dilutive grants from the National Institutes of Health, the National Science Foundation, and the 2020 Redesign Dialysis Phase II KidneyX Prize from the Department of Health and Human Services and the American Society of Nephrology, as well as previous investment rounds with Texas Halo Fund, Activated Capital, Health Wildcatters, Cougar Ventures, and Cowtown Angels.

VenoStent is an advanced materials company with patented core technology in polymer engineering. Its first product, SelfWrap, is a slip-on, bioresorbable wrap aimed to eliminate vascular access surgery failure rate of 55-65% in hemodialysis patients. The extra costs to the Centers for Medicare and Medicaid Services (CMS) created by these failures amounts to over $2 billion per year.

VenoStent has a unique ability to modify Shape Memory Polymers (SMPs) to be thermo-responsive near the human body's temperature, enabling SelfWrap to become moldable 'on-site' with tunable degradation rate. This allows for a snug but flexible support structure that helps alleviate vascular access failure. Altogether, VenoStent's solution aims to improve ESRD patients' quality and length of life and reduce the burden of chronic diseases on the healthcare system.